{"type":"rich","version":"1.0","title":"Choosing Appropriate Covid-19 Prevention Strategies","description":"Charles Vega, MD, FAAFP\nClinical Professor, Department of Family Medicine\nUC Irvine School of Medicine\nSanta Ana, CA\n\nDisclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Exact Sciences, GSK\n\nStefan Gravenstein, MD, MPH\nProfessor of Medicine\nBrown University\nProvidence, RI\n\nDisclosures: Advisor, Consultant, Fee For Service Recipient: AstraZeneca, Genentech, GSK, Moderna, Pfizer, Sanofi; Speakers Bureau: Moderna, Sanofi; Grant/Research Funding: Genentech, GSK, Moderna, Pfizer, Sanofi\n\nElie Saade, MD, MPH\nAssociate Professor of Medicine\nMedical Director, UH Infection Control\nCase Western Reserve University\nCleveland, Ohio\n\nDisclosures: Grant/Research Funding: Johnson & Johnson, Pfizer, Shionogi\n\nActivity Overview\n\nCOVID-19 remains a significant challenge for health care systems, contributing to lengthy hospitalizations, long-term health complications, and costly economic burdens. High-risk populations remain vulnerable to severe disease outcomes, with prevention remaining a key component of management. This CME-certified Medical Crossfire® podcast is the second in a 3-part series titled Primary Care Playbook Podcast: Advancing COVID-19 Prophylaxis in Community Practice. In this activity, 3 expert faculty in Family Medicine, Geriatric Medicine, and Infectious Disease exchange unique perspectives and discuss practical approaches to choosing appropriate COVID-19 prevention strategies in clinical practice, including pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), individualized patient selection, and shared decision-making for patients at high risk of severe disease.\n\nFDA Approves Ensitrelvir for Postexposure Prophylaxis of COVID-19\n\nOn June 1, 2026, the U.S. Food and Drug Administration has approved ensitrelvir for postexposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with active COVID-19. The approval marks the first oral antiviral option in the United States indicated to help prevent COVID-19 after a known exposure.\n\nEnsitrelvir is a SARS-CoV-2 main protease inhibitor administered as a 5-day oral regimen. Its approval was supported by results from the Phase 3 SCORPIO-PEP trial, in which ensitrelvir reduced the risk of symptomatic COVID-19 by 67% compared with placebo through Day 10 in exposed, uninfected individuals.\n\nTarget Audience\n\nThis educational activity is intended for primary care physicians (PCPs), infectious disease (ID) specialists, critical care physicians, hospitalists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the treatment of COVID-19.\n\nLearning Objectives\n\nUpon successful completion of this activity, you should be better prepared to:\n\nDescribe unmet needs in the prevention and management of COVID-19.\nAssess emerging clinical trial evidence informing the use of current and investigational therapies for the prevention of COVID-19.\nImplement individualized strategies for patients at risk of COVID-19 tailored to disease severity and patient-specific factors.","author_name":"PER Podcast Sessions","author_url":"https://audioboom.com/channels/5061664-per-podcast-sessions","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/42834368/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}